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philia; platelets; serum alkaline phosphatases; sGOT; sGPT; serum 
albumin; serum CEA; serum LDH; serum NSE; serum CYFRA
• Tumour biology: p53 ; Bcl-2 ; microvessel density ; VEGF; EGFR; 
c-erbB-2; Ki-67; Ras ; COX2...
The International Association for the Study of Lung Cancer (IASLC) 
staging project has allowed obtaining a huge data basis, making pos-
sible prognostic factors analyses for survival with a strong power. An 
ad hoc subcommittee to perform the analysis was created with the 
participation of Kari Chansky, John Crowley, Peter Goldstraw, Jan van 
Meerbeeck and Jean-Paul Sculier (chairperson). Due to the retrospec-
tive data collection, the data basis is heterogeneous with a lot of miss-
ing data and multiple potential prognostic variables are not present. 
For NSCLC, the analyses focused on the 12,428 stage I-IV cases for 
which we had clinical staging with the necessary descriptors and good 
data for age, sex, performance status, and histological cell type. A 
smaller subset of the advanced stage cases also contained good data 
for the following laboratory values: calcium, serum albumin, serum 
sodium, haemoglobin, and white blood cell count.
Our ﬁrst objective was to determine how best to model age, perfor-
mance status (P.S.), sex, histological cell type, and IASLC stage (i.e. 
the new staging system proposed by the IASLC), using the full set of 
cases. All those variables were found signiﬁcant prognostic factors in 
univariate analyses. Based on these results, we obtained, with a Cox 
regression model, the output of p-values and hazard ratios, shown in 
the table.
Variable p HR
Age (continuous) <.0001 1.01
Male <.0001 1.20
PS 1 <.0001 1.38
PS 2 <.0001 1.32
PS 3/4 <.0001 3.77
Squamous histology (vs. others) 0.1841 1.12
Stage II (vs. I) <.0001 1.86
Stage IIIA (vs. I) <.0001 2.85
Stage IIIB/IV (vs. I) <.0001 5.17
We also looked at global signiﬁcance tests for squamous histology 
+ squamous X stage interaction terms (P=.0048) and for the sex X 
squamous cell type interaction term (P=.012). All terms seem to be 
necessary for the model. The largest effect for squamous histology is in 
the stage I females.
Concerning laboratory data, we restricted our analyses to the IASLC 
stage IV cases. For each laboratory parameter, we used the commonly 
accepted normal range to our data. We found that the upper or lower 
limits (depending on which was relevant for a particular laboratory 
variable) provided very optimal cut-points in our database. So we 
modelled the laboratory variables using these cut-points, in conjunction 
with an ordered performance status variable, age (75 year cut-point) and 
sex, having determined that histology was not important in advanced 
NSCLC. The number of patients respectively assessable for calcium, 
serum albumin, serum sodium, haemoglobin, and white blood cell count 
were 1318, 1889, 1719, 1566 and 2128. Each of the ﬁve laboratory vari-
ables were found to be signiﬁcant prognostic factors for survival. 
Further analyses are ongoing, including those about SCLC and histo-
logical subtypes.
As there were no information available in the IASLC retrospective data 
basis for the potential prognostic role of biological molecular markers 
and of FDG-PET, it was decided to conduct, in collaboration with the 
ELCWP (European Lung Cancer Working Party), evidence medicine-
based literature reviews about those factors. 
There are more than 5,000 published original articles on tissue molecu-
lar biological prognostic factors in lung cancer, with a very variable 
methodological quality. We decided to restrict our review to published 
meta-analyses and identiﬁed as potential good prognostic variable : bcl-
2 (Martin et al,) and as poor prognostic variables : TTF1 (Berghmans 
et al), Cox2 (Mascaux et al), EGFR (Nakamura et al, Meert et al), ras 
(Mascaux et al, Huncharek et al), Ki67 (Martin et al), HER2 (Meert 
et al, Nakamura et al), VEGF (Delmotte et al), microvascular density 
(Meert et al), p53 (Steels et al, Mitsudomi et al, Huncharek et al), aneu-
ploidy (Choma et al). The prognostic value of those molecular markers 
for survival has been determined by univariate analyses, the only way 
to proceed with literature-based meta-analyses. We recommend to 
determine their independent role as prognostic factors by multivariate 
analyses taking into consideration the classical factors such as stage, 
sex, PS, age and some routine biological tests. This approach should be 
included in the future prospective study of the IASLC staging project.
The number of studies published on the prognostic value of the primary 
tumour SUV max (standardized uptake value) measured on FDG-PET 
for survival in NSCLC is much more limited. In the systematic review 
conducted by the ELCWP for the IASLC Staging Project (Berghmans, 
Paesmans, Dusart et al), 14 studies were identiﬁed, with 11 eligible 
for a literature-based meta-analysis including NSCLC only. They were 
published between 1998 and 2006. Numbers of patients ranged from 38 
to 162 (total : 1108); 9 studies identiﬁed a high SUV as a poor prognos-
tic factor for survival and 2 concluded to a non signiﬁcant effect. The 
meta-analysis revealed is that SUV max measured on primary tumour 
was a highly signiﬁcant poor prognostic factor for survival (HR : 2.13; 
95% conﬁdence interval : 1.54-2.95). The next step is to conﬁrm these 
results in a meta-analysis based on individual patients data allowing 
performing multivariate analysis taking into account well known prog-
nostic factors. We have already recommended to consider SUV max in 
the future prospective study of the IASLC staging project.
In conclusion, the signiﬁcant useful independent prognostic factors 
for survival identiﬁed by the IASLC staging project in patients with 
NSCLC are stage, sex, age and performance status. Further analyses 
are ongoing concerning some potentially prognostic routine laboratory 
variables : calcium, serum albumin, serum sodium, haemoglobin, and 
white blood cell count. Literature reviews based on meta-analyses have 
identiﬁed some possible prognostic markers such as bcl-2, TTF1, Cox2, 
EGFR, ras, Ki67, HER2, VEGF, microvascular density, p53, aneu-
ploidy. A meta-analysis based on the literature suggests that the primary 
tumour SUV max measured on FDG-PET is a highly signiﬁcant poor 
prognostic factor for survival in NSCLC. 
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Background: Small cell lung cancer (SCLC) is usually classiﬁed us-
ing the limited and extensive deﬁnition. The Tumor Node Metastasis 
(TNM) classiﬁcation should also be applicable to SCLC but it has only 
been reported in small surgical series. The current analysis looks to the 
impact of the TNM systems on the clinical staging of SCLC and of the 
new International Association for the Study of Lung Cancer (IASLC) 
proposals.
Methods: Using the IASLC database, survival analyses were performed 
for clinically staged patients. Prognostic groups were compared and the 
new IASLC TNM proposals were applied to this population and to the 
Surveillance, Epidemiology and end Results (SEER) database.
Results: The IASLC database contained 12,620 eligible cases of small 
cell histology. TNM staging was available for 8088 patients. Survival 
was directly correlated to both T and N stage. Differences were more 
pronounced in patients without mediastinal or supraclavicular nodal 
involvement. Clinical Union Internationale Contre Le Cancer (UICC) 
stage grouping also differentiates survival except between 1A and 1B. 
Patients with pleural effusion regardless of the cytology have an inter-
mediate prognosis between limited and extensive disease. The IASLC 
proposals for the 7th edition of the TNM classiﬁcation also apply to this 
series of SCLC and to the SEER database.
Conclusion: TNM staging is recommended for SCLC and stratiﬁca-
tions by stage I-III should be incorporate in clinical trials of early stage 
disease. Further studies are needed to clarify the impact of pleural effu-
sion and the extent of N3 disease.
Eli Lilly and Company provided funding to support the International 
Association for the Study of Lung Cancer Staging Committee’s work 
to establish a database and to suggest revisions to the 6th Edition of the 
TNM classiﬁcation for Lung Cancer through a restricted grant. Lilly 
had no input into the committee’s analysis of the data, or into their sug-
gestions for revisions of the staging system.
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Lung cancer frequently involves the skeleton with 30 - 40% of lung 
cancer patients developing bone metastasis. Tumors can have multiple 
deleterious effects on the skeleton including hypercalcemia, bone 
metastasis and treatment induced bone loss. Over 350,000 people per 
year in the United States die with bone metastases, and once tumors 
metastasize to bone, the patients are incurable. Tumor involvement of 
the skeleton can result in severe bone pain, pathologic fractures, and 
life threatening hypercalcemia. In addition, lung cancer can produce cy-
tokines and growth factors such as parathyroid related protein (PTHrP), 
which can act as a hormone and induce increased bone resorption and 
hypercalcemia at sites distant from the tumor. When tumors metastasize 
to the skeleton, they can form either blastic metastasis, in which new 
bone is formed rapidly but the bone is of poor quality, or lytic bone me-
tastasis, where bone is destroyed. In lung cancer, lytic bone metastases 
are the most common type of metastases. When lung cancer homes to 
the bone, it induces bone destruction, and this bone destructive process 
releases and activates growth factors stored in the bone, to stimulate the 
growth of the tumors. Thus, a vicious cycle is set up where the tumor 
growth induces bone destruction and the bone destructive process 
increases the growth of the tumor. Further, when tumors home to the 
bone, adhesive interactions between tumor cells and marrow stromal 
cells increase angiogenesis and make the tumors more chemoresistant. 
Tumors ursurp the normal bone remodeling process and increase osteo-
clast activity by upregulating the RANK/RANK Ligand/osteoproteger-
in signaling pathway that plays a critical role in normal bone remodel-
ing. Once in the bone marrow microenvironment, lung cancer cells 
secrete factors that increase expression of RANK Ligand, which drives 
osteoclast formation and decreases expression of the RANK Ligand 
decoy receptor, osteoprotegerin (OPG) which blocks normal osteoclast 
formation. This shifts the normal balance between RANK Ligand and 
osteoprotegerin to favor osteoclastogenesis. In addition, in lytic bone 
metastases, osteoblast differentiation is suppressed, further exacerbat-
ing the bone destructive process. Importantly, when tumor cells interact 
with stromal cells, a multiplicity of growth factors that are derived from 
marrow stromal cells and immature osteoblast are also released that 
affect bone metastasis. These factors can induce tumor cell chemotaxis, 
increase adhesion of tumor cells to stromal cells, induce tumor growth 
as well as induce osteoblast and osteoclast differentiation. Using animal 
models of bone metastases, in which tumor cells are injected into the 
left ventrical of mice, groups such as Iguchi and coworkers (Cancer 
Res. 1996,56:4040-3) have shown that bone cancer metastasis from 
lung cancer produce high levels of PTHrP. PTHrP, like parathyroid 
hormone, binds the PTH receptor. PTHrP is released by the lung cancer 
cells, suppresses production of OPG and increases RANK Ligand 
expression on stromal cells. This increase in RANK Ligand stimulates 
osteoclastic bone destruction and increases release of calcium and 
growth factors from bone to stimulate tumor growth, exacerbating a 
vicious cycle between tumor growth and the bone destructive process. 
Miki and coworkers (Int. J. Cancer 2004, 108:511-5) have shown that 
an antibody PTHrP can block bone metastasis in animal models of 
lung cancer. Furthermore, increased PTHrP production by lung cancer 
cells may explain the severe cachexia seen in patients with lung cancer. 
PTHrP can induce cachexia in animal models of bone metastasis, and 
a humanized PTHrP antibody has been developed which blocks the ef-
fects of PTHrP and decreases weight loss in lung cancer models in mice 
(Iguchi et al., J. Bone Mineral Res. 2006, 24:16-19). In addition to bone 
destroying osteolytic metastases, osteoblastic metastases may rarely 
occur in lung cancer. Tumor cells can release factors which stimulate 
new bone formation, but even in osteoblast metastasis, there is ongoing 
bone destruction. Thus, new insights into the pathophysiology of lung 
cancer metastasis have identiﬁed several new therapeutic targets for 
treating bone metastases in lung cancer patients. These include RANK 
Ligand and PTHrP where a neutralizing antibody to RANK Ligand is 
in clinical trial in patients with breast cancer, myeloma, and other bone 
metastases and an antibody to PTHrP. 
